» Articles » PMID: 39988344

Efficacy of Cardiac Myosin Inhibitors Mavacamten and Aficamten in Hypertrophic Cardiomyopathy: a Systematic Review and Meta-analysis of Randomised Controlled Trials

Overview
Journal Open Heart
Date 2025 Feb 23
PMID 39988344
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Unlike other suggested therapies, myosin inhibitors have been shown to change the course of hypertrophic cardiomyopathy by altering the contractile mechanics of cardiomyocytes. This meta-analysis sought to determine the efficacy of mavacamten and aficamten in hypertrophic cardiomyopathy.

Methods: The online databases were searched from inception to July 2024, including the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, ClinicalTrials.gov. The meta-analytical data were pooled using risk ratios (RRs) with 95% CI, standard mean difference (SMD) and SE.

Results: A total of 6 randomised controlled trials with 826 hypertrophic cardiomyopathy patients (mean age±SD up to 59.8±14.2 years in intervention vs 60.9±10.5 years in placebo) were included in our study. Of these, 443 received a cardiac myosin inhibitor and 383 received a placebo. The resting left ventricular outflow tract (LVOT) gradient between the two groups was considerably improved by cardiac myosin inhibitors (MD -57.27; 95% CI -63.05 to -51.49). Significant differences were also observed in the post-Valsalva LVOT gradient between the two groups (MD -55.86; 95% CI -65.55 to -46.18). Significantly decreased left ventricle ejection fraction (LVEF) was also seen (MD -4.74; 95% CI -7.22 to -2.26). The New York Health Association (NYHA) class improvement between the two groups also changed significantly (RR 2.21; 95% CI 1.75 to 2.80). Cardiac myosin inhibitors also caused significant improvement in the Kansas City Cardiomyopathy Questionnaire in a Clinical Summary Score between the two groups (MD 7.71; 95% CI 5.37 to 10.05) and significant reduction in the N-terminal pro-B-type natriuretic peptide (SMD -13.27; 95% CI -17.51 to -9.03) and the cardiac troponin I (SMD -11.90; 95% CI -15.07 to -8.72).

Conclusion: According to our meta-analysis, cardiac myosin inhibitors significantly improve the resting and post-Valsalva LVOT gradient, reduce the LVEF and improve the NYHA class and cardiac biomarkers when compared with the placebo.

Prospero Registration Number: CRD52024586161.

References
1.
Stern J, Markova S, Ueda Y, Kim J, Pascoe P, Evanchik M . A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy. PLoS One. 2016; 11(12):e0168407. PMC: 5156432. DOI: 10.1371/journal.pone.0168407. View

2.
Ding W, Meah M, Stables R, Cooper R . Interventions in Hypertrophic Obstructive Cardiomyopathy. Can J Cardiol. 2023; 40(5):833-842. DOI: 10.1016/j.cjca.2023.12.001. View

3.
Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

4.
Maron B, Maron M . Hypertrophic cardiomyopathy. Lancet. 2012; 381(9862):242-55. DOI: 10.1016/S0140-6736(12)60397-3. View

5.
Papadakis M, Basu J, Sharma S . Mavacamten: treatment aspirations in hypertrophic cardiomyopathy. Lancet. 2020; 396(10253):736-737. DOI: 10.1016/S0140-6736(20)31793-1. View